NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Neuphoria Therapeutics Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026

$3.31+0.01 (+0.30%)

Close on Oct 19, 2026

Market cap: $17.90M
P/E (TTM): –
Dividend yield: –

Neuphoria Therapeutics Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30
Revenue	1.17	16	–	–	–	–	–
Research & Development	–	9.01	9.42	13	–	–	–
General & Administrative	7.44	7.77	8.47	8.91	–	–	–
Operating Expenses	18	17	18	22	–	–	–
Operating Income	-16	-1.13	-18	-22	–	–	–
Interest & Investment Income	0.67	0.17	0.22	0.32	–	–	–
Other Non-Operating Income	2.86	0.29	2.31	0.46	–	–	–
Merger & Restructuring Charges	1.28	–	–	–	–	–	–
Asset Impairment Charges	5.36	0	0	–	–	–	–
Pretax Income	-14	-0.84	-16	-22	–	–	–
Income Tax Expense	-0.14	-0.47	-0.09	-0.14	–	–	–
Net Income	-13	-0.37	-15	-21	–	–	–
EPS (Basic)(per share)	-3.06	-0.23	-18.62	-43.20	–	–	–
EPS (Diluted)(per share)	-3.06	-0.23	-18.62	-43.20	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	4.40	1.62	0.83	0.68	0.63	0.36	0.25
Shares Outstanding (Diluted, Weighted)(shares)	4.40	1.62	0.83	0.68	0.63	0.36	0.25
EBITDA	-16	-0.47	-17	-21	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2026

Gross margin: –
Operating margin: -1401.1%
Net margin: -1145.7%
Return on equity, FY2026: -61.7%

Financial strength

Current ratio: 27.85
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2625.7%

Valuation

P/E ratio: –
Price to sales: 15.24
Price to book: 0.73
Dividend yield: –